QIAGEN Expands Alliance with Protedyne Corporation
Investment of approximately US$ 2.0 million
In addition, QIAGEN will invest approximately US$ 2.0 million in Protedyne. QIAGEN has been granted exclusive access to Protedyne's high throughput automation platform technologies for filter-based nucleic acid sample preparation. This strategic alliance is the result of a successful collaboration announced in June 2004. The first commercial system will be available during Q2 of 2005.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.